Ajanta Pharma Limited (BOM:532331)
Market Cap | 335.81B |
Revenue (ttm) | 45.32B |
Net Income (ttm) | 8.98B |
Shares Out | n/a |
EPS (ttm) | 71.57 |
PE Ratio | 37.40 |
Forward PE | n/a |
Dividend | 54.00 (2.01%) |
Ex-Dividend Date | Nov 6, 2024 |
Volume | 1,465 |
Average Volume | 2,897 |
Open | 2,670.55 |
Previous Close | 2,678.15 |
Day's Range | 2,659.30 - 2,698.60 |
52-Week Range | 2,022.05 - 3,485.75 |
Beta | n/a |
RSI | 62.81 |
Earnings Date | May 2, 2025 |
About Ajanta Pharma
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited ... [Read more]
Financial Performance
In 2023, Ajanta Pharma's revenue was 42.09 billion, an increase of 12.45% compared to the previous year's 37.43 billion. Earnings were 8.16 billion, an increase of 38.81%.
Financial StatementsNews

Stocks to buy today on brokerages’ call: IndiGo, Ajanta Pharma, TBO, HDFC Bank, Vodafone Idea among top picks – Check investment target
Several brokerage firms have issued fresh calls on select Indian stocks, highlighting investment opportunities and risks across sectors. While these are views expressed by the respective brokerage hou...

Jefferies initiates Buy on Ajanta Pharma, sees 11% upside due to strong presence in branded generics markets
Jefferies has initiated coverage on Ajanta Pharma with a ‘Buy’ call, projecting an upside of 11% from the current market price of ₹2,574.00 (as of April 11, 2025). The brokerage has set a target price...

Stocks to watch today: Interglobe Aviation, Ajanta Pharma, HDFC Bank, Vodafone Idea, Hindalco, TBO, L&T in focus on brokerage reports
A host of stocks are likely to remain in the spotlight today as several brokerages have issued fresh commentary and call actions, including upgrades, initiations, and revised target prices. Among the ...

Ajanta Pharma Q3FY25 results: Revenue rises 4% YoY to Rs 1,146 crore, PAT Up 11% to Rs 233 crore
According to IQVIA MAT December 2024 data, Ajanta Pharma’s India growth was 11%, outpacing the Indian Pharmaceutical Market (IPM) growth of 8%.

Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%
The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...

Ajanta Pharma declares first interim dividend of ₹28 per share for FY25
Ajanta Pharma Ltd. has announced its first interim dividend for the financial year 2024-25. Each share with a face value of ₹2 will receive a dividend of ₹28, totaling an outlay of ₹350 crore. The com...

Ajanta Pharma Q2 FY25 Results: Revenue rises 15% to ₹1,187 crore, net profit grows 11% to ₹216 crore
Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, has released its Q2 FY25 results, showcasing a strong performance for the quarter and half-year ending on 30th September 2024. Key H...